Abstract
In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Current Signal Transduction Therapy
Title:MicroRNA and Bone Tumor: To Up Date
Volume: 9 Issue: 3
Author(s): Huichao Wang, Ruiqiang Zhang, Yudong Jia, Xiaodong Zhang, Yingjie Zhu, Ying Zhang, Xiantao Chen, Xiaoqiang Zhang, Litao Cai, Hanzheng Zhao, Wuyin Li and Youwen Liu
Affiliation:
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Abstract: In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Export Options
About this article
Cite this article as:
Wang Huichao, Zhang Ruiqiang, Jia Yudong, Zhang Xiaodong, Zhu Yingjie, Zhang Ying, Chen Xiantao, Zhang Xiaoqiang, Cai Litao, Zhao Hanzheng, Li Wuyin and Liu Youwen, MicroRNA and Bone Tumor: To Up Date, Current Signal Transduction Therapy 2014; 9 (3) . https://dx.doi.org/10.2174/1574362410666150116235118
DOI https://dx.doi.org/10.2174/1574362410666150116235118 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Carvacrol Suppresses Human Osteosarcoma Cells via the Wnt/β-Catenin Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Nano Traditional Chinese Medicine: Current Progresses and Future Challenges
Current Drug Targets Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry PACAP is Implicated in the Stress Axes
Current Pharmaceutical Design Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Cytotoxicity of a Vanadyl(IV) Complex with a Multidentate Oxygen Donor in Osteoblast Cell Lines in Culture
Medicinal Chemistry Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Recent Developments in the Synthesis and Biological Activity of Muramylpeptides
Current Medicinal Chemistry